{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-097145","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.525051+00:00","generated_at":"2026-05-30T01:00:32.801186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Unicycive Q3 net loss $4.1M; OLC NDA accepted with PDUFA June 2025","bullets":["Net loss $4.1M vs $4.4M YoY; cash $32.3M expected to fund into 2026.","FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.","OLC patient survey: 79% preferred OLC over prior therapy; 98% said easy to take.","UNI-494 Phase 1 completed; plans to request FDA meeting by end of 2024.","Added to Russell Microcap Index effective July 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-097145","json":"https://secwatch.observer/filing/0001213900-24-097145.json","markdown":"https://secwatch.observer/filing/0001213900-24-097145.md","text":"https://secwatch.observer/filing/0001213900-24-097145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/0001213900-24-097145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/ea0220889-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:00:32.801186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}